Lynparza Poised To Bring Targeted Therapy To Prostate Cancer
Executive Summary
The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous recombination repair (HRRm) gene mutations.
You may also be interested in...
Keeping Track: Good News For Deciphera, BMS And Clovis; Bad News For bluebird/BMS, Blueprint And Tonix
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Clovis’s Rubraca Is First PARP For Prostate Cancer, But AZ’s Lynparza Coming Soon
The limitations of launching during the pandemic will make it difficult to capitalize on a short window between the approvals.
AZ's Lynparza Shines Again In Prostate Cancer Study
With a PDUFA date fast approaching, AstraZeneca has presented more data from the PROfound study, this time showing that Lynparza improved OS compared to hormonal therapies in men with advanced castration-resistant prostate cancer with BRCA1/2 or ATM mutations.